Predicted cardiovascular risk reduction with tirzepatide vs. semaglutide: interpretative considerations from the SURMOUNT-5 post hoc analysis
European Heart Journal Open · 05.03.2026 · 6 (2)
DOI: 10.1093/ehjopen/oeag071 ↗Kurz gefasst
Kommentar in der Zeitschrift European Heart Journal Open, online erschienen am 05.05.2026. Verfasst von Samit Ghosal und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Nightingale Hospital, 11 Shakespeare Sarani, Kolkata 700071, India. Die Arbeit nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Internal Medicine, Nightingale Hospital, 11 Shakespeare Sarani, Kolkata 700071, India.
- Department of Endocrinology, Manipal Hospitals, Kolkata 700106, India.
ORCID-Profile: Samit Ghosal
Zitieren
APA
Ghosal, S., & Sinha, B. (2026). Predicted cardiovascular risk reduction with tirzepatide vs. semaglutide: interpretative considerations from the SURMOUNT-5 post hoc analysis. European Heart Journal Open, 6(2). https://doi.org/10.1093/ehjopen/oeag071
Vancouver
Ghosal S, Sinha B. Predicted cardiovascular risk reduction with tirzepatide vs. semaglutide: interpretative considerations from the SURMOUNT-5 post hoc analysis. European Heart Journal Open. 2026;6(2). doi:10.1093/ehjopen/oeag071
BibTeX
@article{Ghosal2026,
author = {Ghosal, Samit and Sinha, Binayak},
title = {Predicted cardiovascular risk reduction with tirzepatide vs. semaglutide: interpretative considerations from the SURMOUNT-5 post hoc analysis},
journal = {European Heart Journal Open},
year = {2026},
volume = {6},
number = {2},
doi = {10.1093/ehjopen/oeag071}
}
EUVIMED